A Single Center, Double-blind, Placebo-controlled, Randomized, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SUVN-G3031 after Single Ascending Doses and Multiple Ascending Doses in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 19 Oct 2015
At a glance
- Drugs SUVN G3031 (Primary)
- Indications Alzheimer's disease; Cognition disorders
- Focus Adverse reactions; First in man
- Sponsors Suven Life Sciences
- 19 Oct 2015 Results presented at the annual meeting of the Society for Neuroscience (SFN) 2015, as per Suven Life Science media release.
- 08 Sep 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 13 Apr 2015 Results of single ascending dose studies published in the Media Release.